SCTB-14

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameSCTB-14
Drug Alias NameSCTB14SCTB-14
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-PD-1Anti-Vascular endothelial growth factor
TargetsProgrammed cell death protein 1Vascular endothelial growth factor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSinoCelltech Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSinoCelltech Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A